<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="34256">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02660645</url>
  </required_header>
  <id_info>
    <org_study_id>BLCCR-001</org_study_id>
    <nct_id>NCT02660645</nct_id>
  </id_info>
  <brief_title>Blue Light Cystoscopy With Cysview® Registry</brief_title>
  <acronym>BLCCR</acronym>
  <official_title>Blue Light Cystoscopy With Cysview® Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Photocure</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>KARL STORZ Endoscopy-America, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Photocure</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Registry study to gather more information on the current use of Blue Light Cystoscopy with
      Cysview (BLCC) in urologists' practices.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Data will be captured on specific patient types undergoing Blue Light Cystoscopy with
      Cysview for known or suspected non-muscle invasive bladder cancer. Specific clinical
      questions will be asked.

        1. What is the incremental detection rate with Blue Light Cystoscopy with Cysview over
           conventional white light cystoscopy in each of the seven (7) patient populations? Does
           this translate into lower recurrence/progression rate?

        2. How do the six (6) tumor variables used in the European Association of Urology (EAU)
           risk tables (primary/secondary, recurrence rate, size, multifocality, grade, and
           history of carcinoma in situ (CIS))6 affect this incremental rate?

        3. How does an abnormal cytology or positive or negative fluorescent in situ hybridization
           (FISH) affect the likelihood that Blue Light Cystoscopy with Cysview will detect more
           cancers than white light?

        4. What are the performance characteristics of Blue Light Cystoscopy with Cysview within
           eight (8) weeks of Bacillus Calmette-Guérin (BCG) with respect to improved tumor
           detection and false positive rate compared to conventional white light cystoscopy?

        5. What is the incremental Blue Light Cystoscopy with Cysview detection rate over random
           bladder biopsies alone in patients being evaluated for routine three month restaging
           (group 4) or occult disease (group 5)?

        6. What are the performance characteristics of Blue Light Cystoscopy with Cysview after
           repeated Blue Light Cystoscopy with Cysview evaluations with respect to improved tumor
           detection, false positive rate and safety compared to conventional white light?

        7. Does an abnormal urinalysis help identify patients with inflammation more likely to
           have false positive Blue Light Cystoscopy with Cysview results?

        8. What is the practical learning curve for becoming &quot;proficient&quot; with Blue Light
           Cystoscopy with Cysview?

        9. What is the overall false positive rate with Blue Light Cystoscopy with Cysview?

       10. Can Blue Light Cystoscopy with Cysview make the resection more complete? If yes, is
           this due to improved margins and/or additional tumors seen under blue light?

      The Blue Light Cystoscopy with Cysview Registry is a web-based program supported by Global
      Vision Technologies. Data will be captured longitudinally over two (2) years on patients
      from each enrolled site. Each center will enter their respective site's patient data
      electronically.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Rate of detection of bladder malignancies with Blue Light Cystoscopy with Cysview versus white light cystoscopy alone.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>False-positive detection rates</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete resection rates with Blue Light Cystoscopy with Cysview versus white light cystoscopy alone</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with adverse events considered causally related to Cysview in repeat administration.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Blue Light Cystoscopy with Cysview®</arm_group_label>
    <description>Bladder cancer patients who have undergone Blue light cystoscopy with Hexaminolevulinate hydrochloride (Cysview®) 100mg in 50 milliliters (mL) reconstituted solution instilled intravesically into bladder prior to cystoscopy in operating room (OR). Retention time: 1-3 hours. The Karl Storz D-Light C Photodynamic Diagnostic (PDD) system is used for the cystoscopy procedure at the OR examination.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hexaminolevulinate hydrochloride (HCL)</intervention_name>
    <description>Instillation in bladder</description>
    <arm_group_label>Blue Light Cystoscopy with Cysview®</arm_group_label>
    <other_name>Cysview®</other_name>
    <other_name>Hexvix®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Karl Storz D-Light C Photodynamic Diagnostic (PDD) system</intervention_name>
    <description>Cystoscopy procedure</description>
    <arm_group_label>Blue Light Cystoscopy with Cysview®</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients indicated for transurethral resection of the bladder.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult &gt;18 years old

          -  Suspected or known non-muscle invasive bladder cancer on the basis of a prior
             cystoscopy

        Exclusion Criteria:

          -  Porphyria

          -  Gross hematuria

          -  Known hypersensitivity to hexaminolevulinate or aminolevulinate derivatives
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Siamek Daneshmand, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yngvil Kloster Thomas</last_name>
    <phone>(216) 773-2505</phone>
    <email>Ykt@photocure.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>USC/Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ileana Aldana</last_name>
      <phone>323-865-0702</phone>
      <email>ileana.aldana@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Sia Daneshmand, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ann Schuckman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Soroush Bazargari, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Therese Perrier</last_name>
      <phone>612-625-3319</phone>
      <email>perri084@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Badrinath Konety, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Weight Chris, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laureen Hemsley, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolina Urology Partners</name>
      <address>
        <city>West Columbia</city>
        <state>South Carolina</state>
        <zip>29169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicol Brandon</last_name>
      <phone>704-414-2870</phone>
      <phone_ext>2809</phone_ext>
      <email>Nicol.brandon@carolinaurologypartners.com</email>
    </contact>
    <investigator>
      <last_name>T. Brian Willard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Lamb, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Scott Sweazy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Keith Birghtbill, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Stotzer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Bazargani ST, Shah SH, Djaladat H, et al. Blue Light Cystoscopy For Diagnosis of Urothelial Bladder Cancer: Results: From A Prospective Registry. Poster presented at: The Annual meeting of Society of Urologic Oncology; December 2015; Washington, D.C.</citation>
  </results_reference>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 17, 2016</lastchanged_date>
  <firstreceived_date>January 6, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cysview</keyword>
  <keyword>Hexaminolevulinate</keyword>
  <keyword>Hexvix</keyword>
  <keyword>NMIBC</keyword>
  <keyword>BLCC</keyword>
  <keyword>Blue Light Cystoscopy with Cysview</keyword>
  <keyword>Cystoscopy</keyword>
  <keyword>TURBT</keyword>
  <keyword>TUR</keyword>
  <keyword>Fluorescent cystoscopy</keyword>
  <keyword>Non-muscle invasive bladder cancer (NMIBC)</keyword>
  <keyword>Transurethral resection (TUR)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aminolevulinic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
